| Therapeutic drug monitoring of oral targeted antineoplastic drugs A Mueller-Schoell, SL Groenland, O Scherf-Clavel, M van Dyk, ... European journal of clinical pharmacology 77, 441-464, 2021 | 151 | 2021 |
| Perspectives on model‐informed precision dosing in the digital health era: challenges, opportunities, and recommendations F Kluwe, R Michelet, A Mueller‐Schoell, C Maier, L Klopp‐Schulze, ... Clinical Pharmacology & Therapeutics 109 (1), 29-36, 2021 | 44 | 2021 |
| Early survival prediction framework in CD19-specific CAR-T cell immunotherapy using a quantitative systems pharmacology model A Mueller-Schoell, N Puebla-Osorio, R Michelet, MR Green, A Künkele, ... Cancers 13 (11), 2782, 2021 | 24 | 2021 |
| Obesity alters endoxifen plasma levels in young breast cancer patients: a pharmacometric simulation approach A Mueller‐Schoell, L Klopp‐Schulze, W Schroth, T Mürdter, R Michelet, ... Clinical pharmacology & therapeutics 108 (3), 661-670, 2020 | 20 | 2020 |
| Integrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifen L Klopp-Schulze, A Mueller-Schoell, P Neven, SLW Koolen, ... Frontiers in pharmacology 11, 513012, 2020 | 20 | 2020 |
| Pharmacology of doping agents—mechanisms promoting muscle hypertrophy MK Parr, A Müller-Schöll AIMS Molecular Science 5, 131-159, 2018 | 20 | 2018 |
| Developing a nationwide infrastructure for therapeutic drug monitoring of targeted oral anticancer drugs: the ON-TARGET study protocol AM Mc Laughlin, E Schmulenson, O Teplytska, S Zimmermann, P Opitz, ... Cancers 13 (24), 6281, 2021 | 11 | 2021 |
| Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on … P Opitz, S Zimmermann, AM Mc Laughlin, L Müller, S Fuxius, G Illerhaus, ... Journal of Pharmaceutical and Biomedical Analysis 221, 115033, 2022 | 5 | 2022 |
| Simulation-based assessment of the impact of non-adherence on endoxifen target attainment in different tamoxifen dosing strategies A Mueller-Schoell, L Klopp-Schulze, R Michelet, M van Dyk, TE Mürdter, ... Pharmaceuticals 14 (2), 115, 2021 | 5 | 2021 |
| Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling AM Mc Laughlin, PA Milligan, C Yee, M Bergstrand CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1577-1590, 2023 | 3 | 2023 |
| Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review M Van Dyk, N Bulamu, C Boylan, AM Mc Laughlin, G Kichenadasse, ... BMJ open 11 (8), e047173, 2021 | 2 | 2021 |
| Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups A Mueller-Schoell, R Michelet, L Klopp-Schulze, M van Dyk, TE Mürdter, ... Cancers 13 (10), 2432, 2021 | 2 | 2021 |
| TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16) I Colombo, KL Koster, L Holer, S Haefliger, M Rabaglio, S Bastian, ... European Journal of Cancer, 113588, 2024 | 1 | 2024 |
| Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy AM Mc Laughlin, C Yee Journal for immunotherapy of cancer 11 (4), 2023 | 1 | 2023 |
| CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications A Mueller-Schoell, R Michelet, F Weinelt, C Kloft, G Mikus Archives of Toxicology 95 (8), 2867-2870, 2021 | 1 | 2021 |
| 575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: dose escalation part of a multicenter open-label phase I trial (SAKK 65/16) D Hess, I Colombo, S Haefliger, S Bastian, M Rabaglio, Y Metaxas, ... Annals of Oncology 31, S490, 2020 | 1 | 2020 |
| Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort AM Mc Laughlin, T Helland, F Klima, SLW Koolen, RHN van Schaik, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). D Hess, I Colombo, S Haefliger, M Rabaglio, S Bastian, M Schwitter, ... Journal of Clinical Oncology 40 (16_suppl), 3027-3027, 2022 | | 2022 |
| BETWEEN-ASSAY VARIABILITY MIGHT EXPLAIN DIFFERENCES IN PROPOSED Z-ENDOXIFEN EFFICACY THRESHOLDS-EXPLORATORY ANALYSIS RESULTS OF THE CYP2D6 PERCENTAGE ACTIVITY ENDOXIFEN MODEL … A Mc Laughlin, T Helland, R Michelet, G Mikus, D Hertz, C Kloft CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S77-S77, 2022 | | 2022 |
| Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review M Van Dyk, C Boylan, R Michelet, AM Mc Laughlin, G Kichenadasse, ... BMJ open 12 (1), e053308, 2022 | | 2022 |
Robin MicheletSenior scientist, Freie Universität BerlinVerified email at fu-berlin.de
